A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00994123. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Three Groups of Patients With Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT00994123
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Enrollment
- 162 participants
Conditions and interventions
Conditions
Interventions
- MM-121 Drug
- Erlotinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2010
- Primary completion
- Oct 31, 2014
- Completion
- May 31, 2015
- Last update posted
- Aug 21, 2016
2010 – 2015
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35294 | — |
| Not listed | Tucson | Arizona | 85715 | — |
| Not listed | Loma Linda | California | 92354 | — |
| Not listed | Sacramento | California | 95817 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Tampa | Florida | 33612 | — |
| Not listed | Atlanta | Georgia | 30322 | — |
| Not listed | Lafayette | Indiana | 47905 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Buffalo | New York | 14263 | — |
| Not listed | New York | New York | 10065 | — |
| Not listed | Cincinnati | Ohio | 45267 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Pittsburgh | Pennsylvania | 15232 | — |
| Not listed | Charleston | South Carolina | 29425 | — |
| Not listed | Nashville | Tennessee | 37232 | — |
| Not listed | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00994123, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2016 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00994123 live on ClinicalTrials.gov.